A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma

Tang, Hua; Feng, Hai; An, Shi Min; Badakhshi, Harun; Deng, Jiaying; Zhang, Jun Hua; Chen, Yun; Zhang, Zhen; Guo, Xinying; Jiang, Guo Liang; Zhao, K.

doi:10.1097/coc.0000000000000069

Cited by 24 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The grade ≥ 3 haematological toxicity rates of TP are 30.6-73.7% [5, 9, 14]. In our study, the grade ≥ 3 haematological toxicity rate was 11.3%, which was lower than the results reported in a TP-based group study.…”

Section: Discussioncontrasting

confidence: 83%

“…The combination of paclitaxel and cisplatin (TP) is the most commonly used regimen, and the response rates among advanced and metastatic patients with oesophageal cancer are approximately 46%–59% [5–7], with a median survival of 6.9 to 13 months [5, 6, 8]. Radiotherapy concurrent with a monthly schedule of TP resulted in 3-year overall survival (OS) and local failure rates of 41% and 27.6% but a relatively higher haematological toxicity, resulting in neutropaenia grades 3 and 4 in 30.3% and 31.6% of cases, respectively [9]. Increased toxicity with no improvement in OS compared with the PF regimen was associated with the TP regimen for advanced oesophageal cancer [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

Chen

et al. 2017

Radiat Oncol

Self Cite

View full text Add to dashboard Cite

BackgroundA phase II study was performed to investigate the safety and efficacy of weekly doses of combined paclitaxel and 5-fluorouracil (5-FU) with concurrent radiation therapy, followed by 2 cycles of consolidation chemotherapy to treat patients with advanced oesophageal carcinoma.MethodsThe eligibility criteria included local, advanced, newly diagnosed and postoperative local regional lymph node metastasis; an Eastern Cooperative Oncology Group (ECOG) score of ≤ 2; and adequate organ function. Patients received chemoradiotherapy consisting of radiotherapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) and concurrent paclitaxel (50 mg/m2) and 5-FU (300 mg/m2) for 96 h on days 1, 8, 15, 22, and 29. The two-cycle consolidation chemotherapy protocol included paclitaxel (175 mg/m2) plus continuously infused 5-FU (1800 mg/m2) for 72 h administered on days 57 and 85, after concurrent chemoradiotherapy.ResultsBetween February 2012 and August 2013, 53 patients with oesophageal carcinoma were enrolled in the study. Among these patients, 33 (62.2%) were newly diagnosed and 20 (37.7%) had postoperative local regional lymph node metastasis. The median overall survival (OS) time was 17.9 months (95% CIs = 11.9-23.9), and the median progression-free survival (PFS) time was 12.4 months (95% CIs = 8.6-16.1). Approximately 84.9% (45/53) and 50.9% (27/53) of the patients completed ≥ 5 cycles and all 7 cycles of chemotherapy, respectively. Approximately 86.7% (46/53) of patients completed radiation therapy. The 1-, 2-, and 3-year OS rates were 66.0%, 37.7%, and 35.8%, respectively. The 1-, 2-, and 3-year local control rates were 76.9%, 66.4%, and 66.4%, respectively. Seventeen patients (32%) experienced grade 3 or higher toxicity. Grade 3 to 5 toxicity during chemoradiotherapy included neutropaenia (7.5%), thrombocytopaenia (1.8%), fatigue (7.5%), anaemia (1.8%), dermatitis radiation (1.8%), pneumonitis (5.6%), oesophagitis (9.4%) and vomiting (3.7%).ConclusionsThe combination of weekly doses of paclitaxel and 5-FU was well tolerated and produced comparable results among patients with locally advanced oesophageal cancer. A randomised phase III trial (NCT01591135) comparing paclitaxel plus 5-FU with cisplatin plus 5-FU is on-going at our hospital.

show abstract

Section: Discussioncontrasting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

Chen

et al. 2017

Radiat Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…It therefore seems that weekly nab-PC and cisplatin as a neoadjuvant chemotherapy for locally advanced ESCC might be a promising alternative. Moreover, when compared with results from a phase II study of concurrent chemoradiotherapy for inoperable ESCC [29], our 1-year (90% vs 75%), 2-year (70% vs 54%) and 3-year survival rates (43.3% vs 41%) seem encouraging.…”

Section: Discussionmentioning

confidence: 64%

“…In the study, 100% patients completed 2 cycles of neoadjuvant chemotherapy without dosage reduction. Compared to a phase II study of concurrent chemoradiotherapy using sb-PC plus cisplatin for inoperable ESCC [29], grade 3 and 4 neutropenia was lower (11.5% vs 61.9%). During the adjuvant chemotherapy period, grade 3 and 4 hematologic AEs were observed only in 5 (20.8%) patients.…”

Section: Discussionmentioning

confidence: 71%

“…During the adjuvant chemotherapy period, grade 3 and 4 hematologic AEs were observed only in 5 (20.8%) patients. Triple-modality therapy, including radiotherapy, chemotherapy and surgery, is widely considered to be a standard treatment for locally advanced esophageal cancer [29, 33-40]. It seems, however, that concurrent chemoradiation can be accompanied with more severe toxicities and a greater risk of operative mortality [10, 41-44].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

BackgroundWe carried out a phase II study to evaluate the efficiency and safety of the combination of nanoparticle albumin bound-paclitaxel (nab-paclitaxel) and cisplatin as preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC)ResultsFrom Oct 2011 to Dec 2012, 35 patients were enrolled and received neoadjuvant chemotherapy. Thirty patients underwent surgery and achieved a 100% R0 resection. Pathological complete response (pCR) rate was 13.3% and near pCR rate was 6.7%. Down-staging was achieved in 19 patients. With median follow-up of 37.8 months, 16 patients were still alive. One-, 2- and 3- year overall survival (OS) rate was 90.0%, 70.0% and 43.3%, respectively. This treatment resulted in a median disease-free survival (DFS) of 34.7 months and a median OS of 37.8 months. Median DFS and OS of down-staged patients were significantly longer than those of non-downstaged patients. The grade 4 toxicities during neoadjuvant chemotherapy were limited to neutropenia (2.9%) and vomiting (2.9%).MethodsPatients with locally advanced ESCC (stage IIA to IIIC) and performance status 0-1 were enrolled and received two cycles of nab-paclitaxel (100 mg/m2) on day 1, 8, 22 and 29, and cisplatin (75 mg/m2) on day 1 and 22, followed by resection. Two cycles of adjuvant chemotherapy with the same regimen were given. Postoperative radiotherapy was permitted and decided by radiation therapist.ConclusionWeekly nab-paclitaxel with three-weekly cisplatin seems effective and safe as a neoadjuvant chemotherapy strategy for locally advanced ESCC. Down-staged patients have favorable outcome.ClinicalTrials.gov IdentifierNCT01258192

show abstract

Advances in the Theranostics of Oesophageal Squamous Carcinoma

Cheng

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Oesophageal squamous carcinoma (ESCC) is one of the most lethal human malignancies, and it is a more aggressive form of oesophageal cancer (EC) that comprises over 90% of all EC cases in China compared with oesophageal adenocarcinoma (EAC). The high mortality of ESCC is attributed to the late‐stage diagnosis, chemoradiotherapy resistance, and lack of appropriate therapeutic targets and corresponding therapeutic formulations. Recently, emerging clinical and translational investigations have involved genome analyses, diagnostic biomarkers, and targeted therapy for ESCC, and these studies provide a new horizon for improving the clinical outcomes of patients with ESCC. Here, the latest research advances in the theranostics of ESCC are reviewed and the unique features of ESCC (including differences from EAC, genomic alterations, and microbe infections), tissue and circulating biomarkers, chemoradiotherapy resistance, clinical targeted therapy for ESCC, identification of novel therapeutic targets, and designation of nanotherapeutic systems for ESCC are particularly focused on. Finally, the perspectives for future clinical and translational theranostic research of ESCC are discussed and the obstacles that must be overcome in ESCC theranostics are described.

show abstract

A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma

Abstract: Radiotherapy concurrent with a 3-week schedule of PTX and DDP resulted in an encouraging overall survival rate, but a relatively higher hematological toxicity.

Cited by 24 publications

References 19 publications

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma

Advances in the Theranostics of Oesophageal Squamous Carcinoma

Contact Info

Product

Resources

About